Table 3.
Laboratory Findings Corresponding to One Point in Time During Symptom Onset, Flare (Defined as Clinical Global Impressions-Severity Scale Equal to or Higher Than 4 and Marked as a Worsening Period in Patient Records), or During a Chronic-Static or Progressive Course, Compared with Population Norms
| Laboratory findings | Frequenciesa |
|---|---|
| CBC abnormalities | 26/45 (58%) |
| Elevated ESR | 6/43 (14%) |
| Elevated CRP | 4/37 (11%) |
| Low ferritin | 8/39 (21%) |
| Low vitamin D | 10/36 (28%) |
| TSH abnormalities | 4/40 (10%) |
| Low T4 | 0/40 (0%) |
| Anti-TPO | 4/38 (11%) |
| Transglutaminase antibodies | 2/40 (5%) |
| ANAs | 7/41 (17%) |
| Histone antibodies | 0/31 (0%) |
| Elevated SAA | 3/22 (14%) |
| Complement activation | 13/35 (37%) |
| Low IgG | 4/36 (11%) |
| Low IgA | 3/34 (9%) |
| Low IgM | 0/34 (0%) |
| Elevated IL-1-β | 0/25 (0%) |
| Elevated IL-6 | 1/25 (4%) |
| Elevated IL-8 | 0/25 (0%) |
| Elevated TNF-α | 0/24 (0%) |
| Positive strep/throat culture | 5/10 (50%) |
a
These tests were only assessed in a subsample of participants.
ANAs, antinuclear antibodies; CBC, complete blood count; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; IL, interleukin; SAA, serum amyloid A; TNF-α, tumor necrosis factor-α; TPO, thyroperoxidase; TSH, thyroid-stimulating hormone.